|
|
Gilead Sciences Inc (GILD) |
|
Price: $77.0900
$-0.56 
-0.721%
|
| Day's High:
| $78.62
| Week Perf:
| -1.95 %
|
| Day's Low: |
$ 77.01 |
30 Day Perf: |
-7.73 % |
| Volume (M): |
5,439 |
52 Wk High: |
$ 89.74 |
| Volume (M$): |
$ 419,293 |
52 Wk Avg: |
$74.71 |
| Open: |
$78.00 |
52 Wk Low: |
$57.17 |
|
|
| Market Capitalization (Millions $) |
97,210 |
| Shares
Outstanding (Millions) |
1,261 |
| Employees |
14,400 |
| Revenues (TTM) (Millions $) |
27,043 |
| Net Income (TTM) (Millions $) |
5,539 |
| Cash Flow (TTM) (Millions $) |
640 |
| Capital Exp. (TTM) (Millions $) |
590 |
Gilead Sciences Inc
Gilead Sciences,'Inc. is a biopharmaceutical company that discovers, develops
and commercializes therapeutics to advance the care of patients suffering from
life-threatening diseases worldwide. We have six products that are currently marketed
in the U.S., all of which are also marketed in other countries worldwide. Our
research and clinical programs are focused on anti-infectives, including antivirals
and antifungals. We endeavor to grow our existing portfolio of products through
proprietary clinical development programs, internal discovery programs and an
active product acquisition and in-licensing strategy.
Company Address: 333 Lakeside Drive Foster City 94404 CA
Company Phone Number: 574-3000 Stock Exchange / Ticker: NASDAQ GILD
| GILD is expected to report next financial results on August 07, 2023. |
|
|
|
|
Customers Net Income grew by |
GILD's Customers Net Profit Margin grew to |
23.48 % |
3.14 %
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Agilent Technologies Inc
Agilent Technologies Inc, a Biotechnology and Pharmaceuticals company has released its financial results for the three months ending April 30, 2023. The company's revenue increased by 6.845% to $1.72 billion as compared to $1.61 billion on a year-over-year basis. Meanwhile, the company's profitability showed significant improvement, with profits rising 12.09% to $1.02 from $0.91 in the prior year reporting season.
However, there was a decrease in revenue by -2.221% from $1.76 billion in the preceding period, and profits also fell by -14.29% from $1.19 per share. Despite these reductions, earnings rose by 10.22% from net earnings of $274.000 million reported in the second quarter of the 2023 earnings season a year ago.
|
|
Steris Plc
Steris Plc, a leading biotechnology and pharmaceuticals company, has announced a significant increase in revenue for the most recent fiscal period. The company reported a year-on-year revenue rise of 311.172% to $2.94 billion, which is an impressive figure. However, the company slipped into a net loss of $-0.60. This news is significant and has caused some concern among investors and stakeholders.
Compared to the preceding quarter, the income per share fell from $0.56 per share. On the other hand, revenue doubled by a substantial 322.827% from $696.24 million. In the fourth quarter of 2023, Steris Plc posted a net loss of $-90.386 million, as opposed to the net proceeds of $73.623 million recorded in the same quarter a year before. This decline in profits is concerning and indicates a downward trend.
|
|
Burzynski Research Institute Inc
As a journalist who closely follows the financial performance of various corporations, I find the latest results from Burzynski Research Institute Inc quite intriguing. This small biotech and pharmaceutical firm has reported an operating deficit of $-0.215998 million for the fourth quarter of 2023. While the company has not yet revealed its revenue figures, it is worth comparing these results with the corresponding period from the previous year.
In the fourth quarter of 2022, Burzynski Research Institute Inc had already reported an operating deficit of $-0.131272 million. The fact that the shortfall has further expanded to $-0.216 million in the same quarter of 2023 suggests that the company is going through a turbulent period. However, it's important to note that many businesses face such choppy phases while they try to establish prosperous revenue sources.
|
|
Immunovant Inc
Immunovant Inc, a clinical stage biopharmaceutical company, has reported their financial results for the fiscal period ending March 31, 2023. According to the report, the company generated revenue of $4.098 million, which is a positive sign.
However, the company also reported a net loss of $59.432 million for the same period, higher than the previous year's loss of $47.171 million. The net loss per share has worsened from $1.43 in the previous fiscal year to $1.71 in this fiscal year, indicating that the company is facing some financial challenges.
|
|
Replimune Group Inc
Replimune Group Inc is a biotechnology company that focuses on developing cancer therapies based on the use of oncolytic viruses. The company's goal is to develop a range of therapies that can be used in combination with other cancer treatments to improve patient outcomes.
The recent earnings announcement by Replimune Group Inc has raised concerns among investors, who are worried about the company's current financial situation. The $52.995 million operating loss for the most recent fiscal period is a cause for concern, particularly as the company is expected to report further losses in the coming months.
|
| Per Share |
Current |
| Earnings (TTM) |
4.43 $ |
| Revenues (TTM) |
21.45 $
|
| Cash Flow (TTM) |
0.51 $ |
| Cash |
0.74 $
|
| Book Value |
16.61 $
|
| Dividend (TTM) |
2.96 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
4.43 $
|
| Revenues (TTM) |
21.45 $ |
| Cash Flow (TTM) |
0.51 $ |
| Cash |
0.74 $
|
| Book Value |
16.61 $ |
| Dividend (TTM) |
2.96 $ |
|
|
| |
| Viread |
|
Segment |
|
 |
of total Revenue |
| Truvada |
|
Segment |
|
|
of total Revenue |
| Emtriva |
|
Segment |
|
|
of total Revenue |
| HIV products Total |
|
Segment |
|
|
of total Revenue |
| AmBisome |
|
Segment |
|
|
of total Revenue |
| Other products |
|
Segment |
|
|
of total Revenue |
| Atripla |
|
Segment |
|
|
of total Revenue |
| Letairis |
|
Segment |
|
|
of total Revenue |
| Ranexa |
|
Segment |
|
|
of total Revenue |
| Complera Eviplera |
|
Segment |
|
|
of total Revenue |
| Stribild |
|
Segment |
|
|
of total Revenue |
| Sovaldi |
|
Segment |
|
|
of total Revenue |
| Harvoni |
|
Segment |
|
|
of total Revenue |
| |
|
|
2.26%